Moderate-to-severe Plaque Psoriasis is a skin condition that causes thick, red patches covered with silvery scales, often affecting large areas of the body and causing itching or pain. The study uses a medication called ORKA-001, given as a subcutaneous injection (a shot under the skin) at a dose of 600 mg, to see how it works over a long period.
The main aim of the research is to evaluate the long‑term safety of the treatment. Participants receive the injection at regular intervals and attend clinic visits where doctors check for any side effects, take blood samples, measure vital signs, and perform simple heart tests called electrocardiograms (ECGs). The study is open‑label, meaning everyone knows the medication being used, and it continues for many months to gather enough information.
Effectiveness is looked at by seeing how many people keep very clear skin, using scores such as PASI100 (complete clearance), PASI90 (90 % improvement), and the IGA score (a doctor’s overall rating of the skin). These scores help show whether the skin stays improved over time. The study records these results at each visit to understand the durability of the benefit.
Germany 
Spain 
